In this issue:
YEARS for managing suspected PE
Validating the HERDOO2 rule
Occult cancer screening in unprovoked VTE
PE and DVT risk increased in asthmatics
COPD does not increase recurrent VTE risk
IVC filters for preventing PE
Rivaroxaban vs. aspirin for extended VTE treatment
VTE management practices in Australia
Review of exercise benefits in pulmonary hypertension
Upfront combination therapy reduces RV volumes in PAH
Clinical phenotypes and outcomes of PVOD
Long-term outcomes of dasatinib-induced PAH
Risk stratification model for predicting mortality in PAH
Please login below to download this issue (PDF)